Can Alternating Venetoclax Regimens Improve AML Outcomes?

Published Date: 02 May 2026

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemotherapy Boosts Survival for Older Patients With TNBC

2.

More People Than Previously Believed Have Schizophrenia.

3.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

4.

Hereditary cancer has a rare and underreported cause.

5.

Q&A: Breast cancer facts that could save lives


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot